AMP‐activated protein kinase signaling regulated expression of urea cycle enzymes in response to changes in dietary protein intake. Issue 6 (1st August 2019)

• Record Type: Journal Article
• Authors: Heibel, Sandra K.; McGuire, Peter J.; Haskins, Nantaporn; Majumdar, Himani D.; Rayavarapu, Sree; Nagaraju, Kanneboyina; Hathout, Yetrib; Brown, Kristy; Tuchman, Mendel; Caldovic, Ljubica
• Is Part Of: Journal of inherited metabolic disease. Volume 42:Issue 6(2019)
• Page Start: 1088
• Page End: 1096
• Publication Date: 2019-08-01
• Subjects: amino acids -- AMPK signaling -- dietary protein intake -- gene expression -- phosphorylation -- proteome -- regulation -- signaling -- SILAM -- transcriptome -- urea cycle; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12133
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Abundance of urea cycle enzymes in the liver is regulated by dietary protein intake. Although urea cycle enzyme levels rise in response to a high‐protein (HP) diet, signaling networks that sense dietary protein intake and trigger changes in expression of urea cycle genes have not been identified. The aim of this study was to identify signaling pathway(s) that respond to changes in protein intake and regulate expression of urea cycle genes in mice and human hepatocytes. Mice were adapted to either HP or low‐protein diets followed by isolation of liver protein and mRNA and integrated analysis of the proteomic and transcriptomic data. HP diet led to increased expression of mRNA and enzymes in amino acid degradation pathways and decreased expression of mRNA and enzymes in carbohydrate and fat metabolism, which implicated adenosine monophosphate‐activated protein kinase (AMPK) as a possible regulator. Primary human hepatocytes, treated with 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR) an activator of AMPK, were used to test whether AMPK regulates expression of urea cycle genes. The abundance of carbamoylphosphate synthetase 1 and ornithine transcarbamylase mRNA increased in hepatocytes treated with AICAR, which supports a role for AMPK signaling in regulation of the urea cycle. Because AMPK is either a target of drugs used to treat type‐2 diabetes, these drugs might increase the expression of urea cycle enzymes in patients with partial urea cycle disorders, which could be the basis of a new therapeutic approach.